Financial Highlights
Significant strong financial performance with further transition of revenues to recurring royalties from recently launched products
Revenues up 24% to £72.0m (2014/15: £58.0m)
o Strong growth in royalty revenues, up 56% to £39.2m
o Strong growth in royalties from recently launched inhaled products, up 104% to £25.5m from £12.5m
EBITDA up 43% to £23.2m (2014/15: £16.2m)
Profit after tax up 35% to £5.0m (2014/15: £3.7m)
Basic EPS up 33% to 1.2p (2014/15: 0.9p)
Robust balance sheet with cash and cash equivalents of £99.8m (2015: £90.0m)
